An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Inclusion Criteria:

- The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic
BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender,
height) if chronic renal disease, diabetes, heart failure or hypertensive target organ
damage is present

1. If currently treated: The subject has a documented historical diagnosis of
hypertension AND a post-washout clinic Seated Diastolic BP meeting the above
criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood
Pressure Monitoring)

2. If currently untreated: The subject has elevated Seated Diastolic BP meeting the
above criteria on 3 separate occasions before Randomization, including on Day -1
(or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)

- The subject is male or female and aged 6 to <18 years at Baseline and weighs at least
25 kg

- The subject agrees to continue their previously implemented nonpharmacological life
style modifications if begun prior to Screening. Note: For subjects participating in a
weight loss program, the weight maintenance

Exclusion Criteria:

- The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated
Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and
height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP
measurements at Screening/Visit 1

- The subject has a diagnosis of malignant or accelerated hypertension

- The subject is currently treated with more than 2 antihypertensive agents

- The subject or parent/legal guardian is not willing for the subject's previous
antihypertensive medications to be stopped

- The subject has participated in the intensive, active weight-loss phase of a
weight-loss program within 30 days prior to Screening/Visit 1

- The subject has any of the following: severe renal impairment (eGFR <30 mL/min/1.73 m2
by the Schwartz formula); is currently undergoing dialysis treatment; renovascular
disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in
remission; or serum albumin <2.5 g/dL

- The subject has a history or clinical manifestations of severe cardiovascular,
hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism,
Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease,
cancer, and/or any conditions that would interfere with the health status of the
subject through study participation, or would jeopardize study integrity in the
opinion of the investigator

- The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically
significant left ventricular outflow tract obstruction due to eg, aortic valvular
disease, or is likely to undergo a procedure known to affect blood pressure (eg,
repair of arterial anomalies) during the course of the study

- The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin
value >8.5% at Screening/Visit 1

- The subject has hyperkalemia as defined by the central laboratory's normal reference
range or any pertinent electrolyte disorders at Screening/Visit